Management of pulmonary disease in patients with cystic fibrosis.
about
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosisImmunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosisAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisOxygen therapy for cystic fibrosisImmunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosisActive cycle of breathing technique for cystic fibrosisDuration of intravenous antibiotic therapy in people with cystic fibrosisStandard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosisDuration of intravenous antibiotic therapy in people with cystic fibrosisStandard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosisImmunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosisActive cycle of breathing technique for cystic fibrosisAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisActive cycle of breathing technique for cystic fibrosisOxygen therapy for cystic fibrosisOxygen therapy for cystic fibrosisIdentification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosisMicrobiology of airway disease in a cohort of patients with cystic fibrosis.Active cycle of breathing technique for cystic fibrosisIn vitro and in vivo generation and characterization of Pseudomonas aeruginosa biofilm-dispersed cells via c-di-GMP manipulationRole of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosisLung infections associated with cystic fibrosis.rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease.Evaluation of the ambulatory and home care record: Agreement between self-reports and administrative data.Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung.Molecular mechanisms of pulmonary peptidomimetic drug and peptide transport.Use of suppression-subtractive hybridization to identify genes in the Burkholderia cepacia complex that are unique to Burkholderia cenocepacia.Monocytes from cystic fibrosis patients are locked in an LPS tolerance state: down-regulation of TREM-1 as putative underlying mechanism.Sphingobacterium respiratory tract infection in patients with cystic fibrosis.A 96-well-plate-based optical method for the quantitative and qualitative evaluation of Pseudomonas aeruginosa biofilm formation and its application to susceptibility testing.Quinolones: which generation for which microbe?Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbationDesign and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.Cost of care for individuals with cystic fibrosis: a regression approach to determining the impact of recombinant human DNase.Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis.Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administrationPopulation pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosisPulmonary exacerbations in cystic fibrosis with negative bacterial cultures.New approaches to cystic fibrosis.
P2860
Q24187383-FDA22E54-861B-4F1C-9B2C-863602276A77Q24187829-AECBF97D-01E8-4668-B31B-35FCAC83BF32Q24188054-374F2EE4-FD4C-4073-9639-80D90CF236E1Q24201043-7178AE9B-FCB2-4DAB-B62C-A28D15AAFA87Q24201868-0EA45C36-44AF-45BB-8327-8D9EB6656907Q24202244-4159235C-47EE-40E6-A5A1-0AEA53739541Q24202855-A2FB1354-6919-47CC-96A0-7574E714D346Q24203005-04549081-99B2-4BED-9598-50DBB148710FQ24234667-FAFF30BA-E697-46D8-B169-BE35187ED03CQ24234955-0613CE6F-3B11-462C-948B-3E6299F5AAFEQ24235470-C3451817-9361-4A77-862B-D6DF9EB28814Q24236614-A34FBDFB-7A6D-4299-AD42-28D0B59A0265Q24240388-5181D16C-88D0-4BE4-8ED9-95C9808EA27AQ24240423-73A9230B-BCE3-4BC3-9D47-64032AB67AAFQ24241181-6D9D57CB-D0C7-4A36-A262-0EB0F3BC1BE5Q24245714-D89ECF43-776E-4755-B38A-60552440272DQ24550797-AD6B16A2-3446-40E3-B4FB-357D1204136FQ25256069-0E13DF59-3DD0-4F03-A38C-E66F606E6F96Q26471161-D91F8872-827A-4492-B737-37D80736D91EQ28264802-9FA03723-6718-4C5F-A6E9-747122BF4626Q28492843-0161A91A-22F9-4A03-8D79-6804427387C5Q30080000-522184C7-A1D2-4F58-ABA2-173D94F849E3Q30835288-D727FAFB-7604-425F-AF52-19933E70C047Q31035337-54DF2492-9F6F-4C28-97AF-29FBB27FBDB8Q33183310-8BA8F1B5-2D72-43CE-98FC-207EB981CDF8Q33198362-BD44254F-CE1A-472E-9BEE-4F3803C33D79Q33219966-AFCFDE6C-DC46-4094-A206-4E34EB9887DFQ33352036-A398460D-0423-45B1-B32D-3808CDC17125Q33520547-A04AE686-18FD-4F5A-97EF-F6A120DEDECBQ33645381-9D69643A-ECE2-449D-92AA-13A4F95DC9C0Q33708968-4372EA2A-6B5A-42F7-9A25-6FA896FB9FA4Q33744911-CF738283-9F77-4E32-9F15-9D40CDF18945Q33836302-6786E206-E115-4EA6-9306-2643D67BDDE9Q33876169-97B47D25-44D0-4970-AD39-E9A60F480549Q33962562-2A514605-8666-4746-93C2-929561A11996Q33966881-86063314-322B-4857-AA14-E7305DD19505Q33979054-2382F189-26FE-4C9C-9BBE-8900A2201460Q33983611-234FD640-7150-4B4E-8AF8-8D8E620164C5Q34118967-6B07801D-598C-47DB-AA99-7058C410029DQ34151234-94AF8C85-3E4F-4A5D-89BF-8B24771C6400
P2860
Management of pulmonary disease in patients with cystic fibrosis.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Management of pulmonary disease in patients with cystic fibrosis.
@en
type
label
Management of pulmonary disease in patients with cystic fibrosis.
@en
prefLabel
Management of pulmonary disease in patients with cystic fibrosis.
@en
P1476
Management of pulmonary disease in patients with cystic fibrosis.
@en
P2093
P304
P356
10.1056/NEJM199607183350307
P407
P577
1996-07-01T00:00:00Z